These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3893505)

  • 1. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
    Cuzick J; Cooper EH; MacLennan IC
    Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
    Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
    Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
    Br J Cancer; 1980 Dec; 42(6):831-40. PubMed ID: 7459218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
    Norfolk D; Child JA; Cooper EH; Kerruish S; Ward AM
    Br J Cancer; 1980 Oct; 42(4):510-5. PubMed ID: 6159910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.
    Child JA; Crawford SM; Norfolk DR; O'Quigley J; Scarffe JH; Struthers LP
    Br J Cancer; 1983 Jan; 47(1):111-4. PubMed ID: 6185132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
    Bataille R; Grenier J
    Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
    Scudla V; Vavrdová V; Budíková M; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
    Scarffe JH; Anderson H; Palmer MK; Crowther D
    Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
    van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
    Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
    Diem H; Fateh-Moghadam A; Lamerz R
    Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.
    Bataille R; Durie BG; Grenier J
    Br J Haematol; 1983 Nov; 55(3):439-47. PubMed ID: 6357266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
    Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
    Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults.
    Buckman R; Cuzick J; Galton DA
    Br J Haematol; 1982 Dec; 52(4):589-99. PubMed ID: 6958312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
    Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary pseudouridine excretion in myelomatosis.
    Sørensen SH; Brown DA; Cooper EH; Kelly KA; MacLennan IC
    Br J Cancer; 1985 Dec; 52(6):863-6. PubMed ID: 3907686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-2-microglobulin: a valuable parameter of stage, prognosis and response to treatment in myelomatosis.
    Bjerrum OW; Plesner T
    Scand J Haematol; 1985 Jul; 35(1):22-5. PubMed ID: 3901240
    [No Abstract]   [Full Text] [Related]  

  • 18. Beta 2 microglobulin in multiple myeloma.
    Alexanian R; Barlogie B; Fritsche H
    Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
    Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
    Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.
    Greipp PR; Lust JA; O'Fallon WM; Katzmann JA; Witzig TE; Kyle RA
    Blood; 1993 Jun; 81(12):3382-7. PubMed ID: 8507875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.